Navigation Links
Oramed to Present at PIONEERS 2016, Presented by Joseph Gunnar
Date:4/28/2016

JERUSALEM, April 28, 2016 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that the Company will participate in the upcoming PIONEERS 2016 conference, presented by Joseph Gunnar & Co. LLC, taking place on May 5, 2016 in New York. Nadav Kidron, CEO of Oramed, will present a corporate overview at the conference.

Presentation Details: 

PIONEERS 2016, presented by Joseph Gunnar
Date:        Thursday, May 5, 2016
Time:        11:30am EDT
Location:    New York Palace Hotel, Hubbard 1, New York City

About Oramed Pharmaceuticals 

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs currently delivered via injection. Established in 2006, Oramed's Protein Oral Delivery (POD[TM]) technology is based on over 30 years of research by top scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801). The Company completed multiple Phase II clinical trials under an Investigational New Drug application with the U.S. Food and Drug Administration. In addition, Oramed is developing an oral GLP-1 analog capsule (ORMD-0901).

For more information, the content of which is not part of this press release, please visit http://www.oramed.com

Forward-looking statements:  This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as "expects," "anticipates," "intends," "plans," "believes," "seeks," "estimates" and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials and revolutionizing the treatment of diabetes with our products. These forward-looking statements are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and finally that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact
Oramed Pharmaceuticals
Ariella Vaystooch
Office: +972-2-566-0001 ext. 2
US: +1-718-831-2512 ext. 2
Email: ariella@oramed.com



'/>"/>
SOURCE Oramed Pharmaceuticals Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Oramed Receives FDA Clearance to Initiate Oral Insulin Trials in the U.S.
2. Oramed Pharmaceuticals Awarded Grant by the Office of the Chief Scientist of Israel
3. Oramed Selected to Present at the 81st European Atherosclerosis Society Congress in Lyon, France, June 2-5, 2013
4. Oramed Pharmaceuticals to Present at IATI-BioMed Conference in Israel
5. Oramed Pharmaceuticals Announces Withdrawal of Proposed Underwritten Public Offering
6. Oramed Pharmaceuticals to Present Findings on Oral Insulin to the American Diabetes Association
7. Oramed to Raise $4,600,000 in Registered Direct Offering
8. Oramed Submits Pre-IND Meeting Request to FDA for its Oral Exenatide Capsule ORMD-0901
9. Oramed Granted Patent in China for its Platform Technology in Oral Delivery of Proteins
10. Orameds Platform Technology in Oral Delivery of Proteins Receives Patent in Russia
11. Oramed Announces Last Patient Out in Phase 2a FDA Trial of its ORMD-0801 Oral Insulin Capsule
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/16/2019)... ... August 16, 2019 , ... SignatureCare Emergency Center has ... Houston, TX including Montrose, Heights, Memorial City, and Bellaire, TX. , The one-day ... Heights, is aimed at helping Houston families get their children caught up on ...
(Date:8/16/2019)... (PRWEB) , ... August 16, 2019 , ... ... Road in Gainesville GA, 30501, is a comprehensive family dental practice that serves ... within general dentistry, cosmetic dentistry , endodontics and restorative dental care. The ...
(Date:8/16/2019)... ... August 16, 2019 , ... OCT Clinical ... it has successfully completed enrollment of 690 patients for a phase III efficacy ... multicenter, randomized, double-blind, placebo-controlled, home use, parallel group clinical trial of MED2002, which ...
Breaking Medicine Technology:
(Date:8/19/2019)... ... August 19, 2019 , ... Nearly ... Organic Skin Care products , the authorized retailer will change its corporate name ... practicing esthetician in Florida providing Eminence Organic Skin Care facials and treatments. DeVries ...
(Date:8/19/2019)... ... August 19, 2019 , ... A July 26 ... owners should be brushing their pets’ teeth twice a day. The acknowledges that, with ... time and suggests that close monitoring and brushing at least twice a week is ...
(Date:8/17/2019)... ... August 17, 2019 , ... Inc. Magazine ... Companies—the Inc. 5000 , For the 2nd Year In a Row, YellowTelescope LLC ... 192% Percent , Inc. magazine today revealed that YellowTelescope LLC (YellowTelescope, SEOversite, and ...
(Date:8/16/2019)... ... August 16, 2019 , ... The ... one-of-a-kind children’s aircraft to Ronald McDonald House Charities in New Hyde Park, Long ... undergoing medical treatments and their family members a comfortable and fun way to ...
(Date:8/15/2019)... ... , ... The ASCP Foundation has launched a campaign to ... closure of Hahnemann University Hospital in Philadelphia, which is affiliated with Drexel University. ... be making hardship grants of up to $2,500 per resident available to assist ...
Breaking Medicine News(10 mins):